Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is characterized by poor outcomes and mutations in the tumour suppressor p53. Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs). First, we identified the optimal NP formulation through comprehensive analyses of release profiles and cellularuptake and cell viability studies. Not only were PTX-loaded NPs superior to PTX in solution, but the combination of PTX-loaded NPs with the antiangiogenic molecular inhibitor BIBF 1120 (BIBF) promoted synthetic lethality specifically in cells with the lossof-function (LOF) p53 mutation. In a xenograft model of endometrial cancer, this combinatorial therapy resulted in a marked inhibition of tumour progression and extended survival. Together, our data provide compelling evidence for future studies of BIBF-and PTX-loaded NPs as a therapeutic opportunity for LOF p53 cancers.
ndometrial cancer (EC) is the most prevalent gynaecological malignancy in the USA 1 , with incidence and mortality on the rise largely because of the obesity epidemic 1 . Importantly, EC is one of only two common cancers that defy the general trend of improvement in incidence and mortality, with survival worse today than in the 1970s 1 . EC is classified into two major subtypes based on clinicopathological properties 2 . Type I EC is well differentiated, typically detected at an early stage, represents 80% of all cases and is associated with a favourable prognosis 2 . In contrast, the poorly differentiated type II EC includes mainly uterine serous carcinoma (USC) and portends a poor prognosis 2 . Although USC represents only 10% of all EC cases, it contributes to 39% of total EC deaths 3 . The mainstay therapy for USC is chemotherapy and/or radiotherapy, a standard that has been in place for over two decades 4 . Although numerous clinical trials have explored molecular inhibitors as monotherapies, they have generally failed to improve survival; however, combinatorial therapies that rationally pair molecular inhibitors with standard chemotherapy may improve outcomes 5 .
Mutations in TP53 (the gene that encodes p53) occur in over 90% of USC 6 and are of three basic functional classes: (1) truncating, frameshift or splice site loss-of-function (LOF) mutations that result in protein instability and a p53-null state, (2) missense mutations that often result in the gain of oncogenic function (GOF) and (3) synonymous/silent mutations that are wild-type (WT) equivalent 7 .
As the guardian of the genome, p53 controls cell cycle checkpoints to allow cells to repair damaged DNA or induce apoptosis 8 . The activation of the cell cycle checkpoints prevents progression into vulnerable phases of the cell cycle during treatment with chemotherapy. For example, paclitaxel (PTX) kills dividing cells in mitosis through stabilizing mitotic spindle microtubules 9 . Enforcing the G2/M checkpoint allows tumour cells to repair DNA before entering mitosis, which leads to chemoresistance 10, 11 . In addition to p53, emerging data suggest that p38MAPK can also maintain the G2/M checkpoint 12, 13 . In cells with LOF p53, p38 is activated as an alternative means to maintain the G2/M checkpoint 14 .
Our group established that the combination of PTX with tyrosine kinase inhibitors (TKIs) induces synergistic cell death specifically in LOF p53 cancer cells because of abrogation of the G2/M checkpoint 15, 16 . Cells arrest in mitosis and die as a result of mitotic catastrophe 15, 16 . This phenomenon is termed synthetic lethality, a historical genetic observation that, in the presence of certain singlegene mutations, the blocking or mutating of a second gene leads to cell death, although neither mutation alone has a phenotype 17 . The concept of synthetic lethality has been explored in several clinical contexts, and the most successful to date is the use of poly (ADP-ribose) polymerase inhibitors in tumours with mutations in BRCA 18, 19 . With respect to synergistic cell death from combining PTX and a TKI, synthetic lethality means capitalizing on the presence of a p53 mutation to block the compensatory survival pathways activated as a result of the mutation. This approach is a novel application of synthetic lethality for p53 mutations given that the majority of studies so far have attempted to restore WT function 20 . The advantage of this approach is that it adds a degree of cancer targeting, as this combination poses specific cytotoxicity only in cancer cells with a LOF p53 mutation, sparing the normal cells that do not carry the mutation.
Building on our previous work, we have developed an innovative approach to enhance significantly the efficacy of PTX + TKI combinatorial treatment for USC.
First, we explored the use of a triple angiokinase molecular inhibitor, BIBF 1120 (BIBF, also known as nintedanib), that inhibits multiple tyrosine kinase receptors (vascular endothelial growth-factor receptors, platelet-derived growth-factor receptors and fibroblast growth-factor receptors (FGFR) 21 ) and induces cell
Synthetic lethality with soluble BIBF + PTX in LoF p53 cells
We first investigated the involvement of the p53 mutational status in the sensitivity of EC cell lines to the combination of BIBF and PTX. Three different EC cell lines that bear different p53 mutations were utilized in the study: Ishikawa cells (WT p53), Hec50co cells (LOF p53 mutation that results in a p53-null status) and KLE cells (GOF p53 caused by R175H mutation). These cells are all WT for the BIBF target, FGFR2 ( Supplementary Fig. 1 ). Cells were incubated with soluble PTX (PTXs) or soluble BIBF (BIBFs) or the combination. Analysis of cell viability revealed that only Hec50co cells with LOF p53 were sensitive to the combination (Fig. 1a) , with a threefold decrease in viability compared to incubation with PTXs or BIBFs as single agents. These data substantiate the dependence of the combination of PTX and BIBF on LOF p53 status.
Emerging studies suggest that sequential or time-staggered drug administration, that is, 'molecular priming' , may improve therapeutic efficacy 26 . However, the concomitant administration of PTXs and BIBFs was superior to sequential administration ( Fig. 1b ). Thus, synthetic lethality does not require molecular priming with BIBF. Calculation of the combination index (CI) demonstrated a pronounced synergy between PTX and BIBF at concentrations as low as 100 nM (Fig. 1c ).
Preparation and characterization of PTX-loaded NPs
Next, we designed a delivery system to enhance the targeted cytotoxic effect of these drugs and overcome the drawbacks of administering soluble drugs in vivo. We chose polymeric NPs because of their ability to offer superior drug stability, higher accumulation in the tumour, enhanced tumour regression and lower systemic side effects as compared with soluble drugs 27 . Biocompatible poly(lacticco-glycolic acid) (PLGA) NPs were prepared utilizing: (1) two different PLGA polymers of different monomer ratios and different molecular weights (75:25, 68 kDa; 50:50, 24-38 kDa) and (2) two different surfactants: polyvinyl alcohol (PVA) and d-α -tocopherol polyethylene glycol 1000 succinate (TPGS). PVA is the most commonly used surfactant in NP fabrication, based on its superior surfactant characteristics 28 . TPGS is a promising surfactant used recently in NP fabrication that has a distinct ability to inhibit P-glycoprotein (P-gp) efflux transporter 29 .
PTX-loaded NPs were prepared using a nanoprecipitation method ( Fig. 2a ), a simple technique capable of producing small nanometre-scale particles with a narrow size distribution.
A NP size < 200 nm potentiates passive targeting to the tumour via the EPR effect, which increases tumour cytotoxicity in vivo compared with that of soluble drugs 25 . All the NPs were < 175 nm in diameter, with a narrow size distribution and negative charge (Table 1) . When TPGS was used as the surfactant, the NPs exhibited smaller hydrodynamic diameters relative to PVA. PTX loading into NPs (PTXp) did not significantly alter the size or zeta potential compared to blank NPs (Blankp). PTXp prepared using PLGA (75:25) and TPGS (PTXp (75/T)) exhibited a 1.8 times higher encapsulation efficiency (EE) and drug loading (DL) compared with PTXp prepared with PVA (PTXp (75/P)). The same trend was achieved when PLGA (50:50) was used to prepare the NPs, and thus a 1.6-fold higher EE and DL was achieved with TPGS (PTXp (50/T)) compared with PVA (PTXp (50/P)). The higher EE and DL with TPGS probably results from the increased affinity of PTX for the hydrophobic vitamin E portion of TPGS embedded in the NP matrix 30 . Higher EE and DL were associated with the use of PLGA (75:25) when compared with PLGA (50:50) with the same surfactant utilized, which is probably because of the higher lactic acid content and therefore superior hydrophobic characteristics.
All the formulations were spherical with smooth surfaces, and loading PTX into the NPs did not affect the integrity or surface morphology when compared to Blankp (Fig. 2b ). There was no significant difference in size between TPGS-and PVA-prepared NPs (for example, Fig. 2b , panels 1 and 2). The discrepancy in NP size estimated using Zetasizer measurements (Table 1) versus scanning electron microscopy (SEM) imaging is probably because the hydrodynamic diameter, as measured by the zeta sizer, tends to overestimate the size of NPs with hydrophilic surfaces. PVA has a higher hydrophilic lipophilic balance value of 18 as compared with 13.2 for TPGS 31 , and thus the higher hydrophilic characteristics and higher hydrodynamic diameter values with PVA relative to TPGS were expected. Confocal imaging confirmed the uptake of rhodamine B (RHD)-loaded NPs (RHDp) by Hec50co cells (Fig. 2c,d ). Transition electron microscopy (TEM) images of PTXp (75/T) confirmed that the particles were spherical and < 175 nm in size ( Fig. 2e ). In cells treated with PTXp (75/T), TEM images confirmed the uptake (black arrows) and cytoplasmic distribution ( Fig. 2f ).
We next studied cytotoxicity as compared with that of PTXs. In Ishikawa and KLE cells, NPs showed comparable decreases in cell viability relative to that of PTXs, with the exception of PTXp (50/T), which exhibited a 36% enhancement in cytotoxicity in the KLE cells compared with that of PTXs ( Fig. 3a ). Interestingly, in Hec50co cells, all the NP formulations except PTXp (50/P) promoted a significant decrease in cell viability, with the most notable effects being with TPGS-emulsified NPs (Fig. 3a ). Dose-response curves validated these findings ( Fig. 3b ). Studies using Blankp confirmed that the cytotoxicity was not due to the NP formulation ( Fig. 3c ). These data demonstrate that PTXp was specific for Hec50co cells with LOF p53 and were superior to PTXs.
Our data also demonstrate that TPGS is superior to PVA in LOF p53 cells. As TPGS has been reported to inhibit drug efflux transporters 29 , we hypothesized that the improved cell killing with PTXp (75/T) and PTXp (50/T) results from the increased intracellular retention of PTX. To test this, we performed flow cytometry cell-uptake experiments utilizing RHDp. As with PTX 32 , RHD is a substrate for the P-gp efflux transporter 33 and can serve as a surrogate for PTX intracellular behaviour. In all three cell lines, RHD accumulation was increased with the use of TPGS as the surfactant as compared with PVA ( Fig. 3d ). For example, the median fluorescence intensity of RHDp (75/T) in Hec50co cells was 11.4 times higher than that of RHDp (75/P), which supports our hypothesis that TPGS increases intracellular drug accumulation.
In addition, RHDp (75/T) exhibited a 5.1-fold increase in fluorescence intensity when compared with that of RHDp (50/T), indicative of a difference in uptake. This could be related to the fact that PLGA (72:25) is more hydrophobic than PLGA (50:50) 34 . Indeed, both Ishikawa and KLE exhibited the same trend in NP uptake, although the magnitude of NP uptake was much higher in KLE cells (similar to that of Hec50co cells). Based on these data, we surmise that Hec50co and KLE cells have higher expressions of efflux transporter(s) relative to Ishikawa cells. Although KLE cells had a higher accumulation of RHDp (75/T) ( Fig. 3d ), this was not reflected in a higher cytotoxicity ( Fig. 3a ). This could be related to the fact that KLE cells are insensitive to PTX when compared with Hec50co cells ( Supplementary Fig. 2 ).
NPs with a higher M w PLGA (75:25) had a slower release profile for PTX compared with the lower M w (50:50) polymer ( Fig. 3e ). These data are consistent with previous results that the higher the M w of the polymer, the longer the polymer chain, the more hydrophobic the polymer and subsequently the slower the degradation and the release of the loaded drug 35 . In addition, polymers with a higher lactic acid content, such as PLGA (75:25), have a higher hydrophobicity and consequently slower interaction with water and a slower degradation and drug release 35 . At the 24 h time point, the PTX release was slightly higher from PTXp (75/T) than from PTXp (75/P). There are two possibilities for the apparent accelerated drug release with TPGS. First, PTX has a high affinity for the vitamin E moiety of TPGS, which is expected to be oriented on the surface of the NPs. This would increase the availability of PTX for release as compared with PVA-emulsified NPs 30 . Another explanation is based on the reported faster release of docetaxel from TPGS-emulsified PLGA NPs. TPGS forms pores at the NP surface and thus increases the exposed surface area to the release media 36 .
In separate experiments using a well-established efflux transporter blood-brain barrier model, we confirmed that the RHDp (75/T) formulation has a robust uptake profile as compared with that of RHDs ( Supplementary Fig. 3 ). We also established that PTXp (75/T) significantly decreased cell viability in a cell model of PTX resistance ( Supplementary Fig. 4 ). Marked cell death in cells treated with PTXp (75/T) but not Blankp (75/T) was confirmed using multiple methods ( Supplementary Fig. 5 ).
PTXp combined with BIBF induces lethality in LoF p53 uSC
PTXp (75/T) was selected as the optimum formulation and used in subsequent combinatorial experiments with BIBF. We first explored the effect of combinatorial treatment on cell cycle progression in Hec50co cells. PTXp (75/T) promoted the accumulation of cells in G2/M, and the addition of BIBFs to PTXp (75/T) resulted in nearly all the cells accumulating at G2/M (Fig. 4a ). In addition to the effects on the G2/M checkpoint, BIBF has been reported to inhibit the P-gp efflux transporter 37 , which would prevent PTX efflux and increase its intracellular concentration.
We next evaluated key G2/M regulators to determine if the combinatorial treatment abrogates the G2/M checkpoint. Phosphorylation of the kinase cdc2 at Tyr15 maintains the G2/M checkpoint, whereas dephosphorylation by the phosphatase cdc25C results in entry into mitosis phase. cdc25C is maintained in an inhibited state through phosphorylation at Ser216, which is mediated by multiple kinases, including p38MAPK. Abrogation of the G2/M checkpoint requires dephosphorylation of cdc25C at Ser216 and phosphorylation at 12 different sites (indicated by a slower migrating band) and dephosphorylation of cdc2 at Tyr15. Dual treatment with BIBFs and PTXp (75/T) resulted in a decreased cdc2 Tyr15 phosphorylation and an increased cdc25C activation ( Fig. 4b ). We also detected an increased phosphorylation of the mitosis marker, histone H3.
Consistent with the data in Fig. 1 , dual treatment produced the most profound decrease in cell viability compared with either drug alone ( Fig. 4c , left panel), indicative of synthetic lethality. In contrast to parental Hec50co cells, Hec50co cells that express a GOF p53 mutant did not show any additional increase in cytotoxicity from the combinatorial treatment over PTXp (75/T) alone ( Fig. 4c ), which demonstrates the requirement for the LOF p53 status for synthetic lethality.
The difference in toxicities caused by the p53 status could be attributed to two possibilities. (1) In the absence of p53, cells rely on the p38 pathway to maintain the G2/M checkpoint 14, 16 , and treatment with a TKI in combination with PTX reduces p38 activation 16, 38 . The GOF p53 cells have evolved an additional mechanism to maintain p38 activation through an increased expression of the upstream kinase MKK3 (ref. 16 ). Hence, treatment with a TKI is not sufficient to abrogate the G2/M checkpoint. (2) The change in p53 status is accompanied by a change in the expression of efflux transporter(s) and thus corresponding differences in PTX intracellular accumulation. Given that BIBF inhibits P-gp (ref. 37 ), this change in drug efflux would alter the cytotoxicity of the combination therapy. The relationship between P-gp expression and p53 status is controversial: Thottassery et al. showed that LOF p53 is associated with upregulation of P-gp (ref. 39 ), whereas Angelis et al. showed that there is no correlation 40 . In addition, a positive correlation between GOF p53 and P-gp overexpression was reported by Sampath et al. 41 .
We therefore performed a cell-uptake experiment to examine if BIBFs increases drug accumulation using RHDp as a surrogate. BIBFs significantly enhanced the accumulation of RHD inside both parental and GOF Hec50co cells for all the tested formulations ( Fig. 4d,e ), with a similar magnitude of increase in both cell lines. These data support the interpretation that the synthetic lethality observed in Fig. 4c probably results from interference with the G2/M checkpoint in LOF p53 cells.
In vivo synthetic lethality and safety of PTXp + BIBFp
We generated PLGA (75/T) NPs loaded with BIBF (denoted as 'BIBFp (75/T)'). The NP size, zeta potential and EE are summarized in Table 1 . SEM of BIBFp (75/T) demonstrated spherical NPs with a smooth surface morphology ( Supplementary Fig. 6 ). The combination therapy of PTXp (75/T) + BIBFp (75/T) promoted a marked decrease in cell viability compared with all the other treatments, including PTXp (75/T) + BIBFs (Fig. 5a ). Thus, BIBF administered in NPs retains synthetic lethality when combined with PTXp (75/T). Like PTX, BIBF is a reported substrate of P-gp (ref. 42 ), and loading BIBF in NPs that contain TPGS may increase the intracellular accumulation and therapeutic effect of BIBF. 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 Studies were extended to an in vivo xenograft model of USC using Hec50co cells. PTXp (75/T) alone impeded tumour growth more than PTXs, which indicates that the delivery of PTX in a NP formulation improves efficacy (Fig. 5b) . Treatment with PTXp (75/T) + BIBFp (75/T) was superior to that of PTXp (75/T) alone, which supports that the combination of BIBF and PTX induces synthetic lethality in vivo. Only the combination therapy of PTXp (75/T) + BIBFp (75/T) significantly inhibited tumour growth as compared with PTXs and naive control. Representative images of mice at day 32 are shown in Fig. 5c .
The combination was the only treatment that significantly increased median survival compared with the naive group (Fig. 5d ). Specifically, treatment with PTXp (75/T) + BIBFp (75/T) was associated with a median survival of 51 days compared with 43, 41 and 39 days when mice were treated with PTXp (75/T), PTXs or saline, respectively. The 18.6% increase in median survival with the combination therapy versus PTXp (75/T) is in line with a clinical study of NSCLC that demonstrated that the combination of BIBF and docetaxel extends survival by 22.3% compared with docetaxel plus placebo 22 . This effect was only observed in NSCLC patients with adenocarcinoma histology. As TP53 mutations also predominate in the adenocarcinoma subtype of NSCLC 43 , we speculate that NSCLC patients that responded in this trial may harbour LOF p53, thus providing support for the concept that synthetic lethality may be applicable to cancers beyond USC.
The in vivo safety of the combination therapy is supported by the stable body weight (Fig. 5e ) and the absence of signs of necrosis or cell death in the heart, lung, liver, spleen or kidney, as measured by haematoxylin and eosin (H&E) (Fig. 5f ).
We also analysed PTX intratumoural drug accumulation using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method ( Supplementary Fig. 7) and found a superior accumulation of PTXp (75/T) compared with that of PTXs (Fig. 5g ). Finally, we examined the biodistribution profile of NPs loaded with a near-infrared fluorescent dye (DiR) because previous studies suggested that only a minor fraction of NPs (0.7%) reaches the tumour 44 . However, at least 10% of DiRp (75/T) accumulated in the tumours ( Supplementary Fig. 8 ). Together, these data substantiate the potential clinical relevance of our preclinical studies.
Conclusions
The data presented here provide compelling evidence that p53 plays a critical role in the response to the combination therapy of PTX and BIBF, such that synthetic lethality only occurs in the setting of LOF p53. Mechanistic studies support that abrogation of the G2/M checkpoint allows cells to prematurely enter mitosis, where they undergo cell death through mitotic arrest. Moreover, the specific NP formulation that consists of PLGA at a monomer ratio of 75:25 and TPGS surfactant improves therapeutic efficacy through enhanced drug uptake and accumulation, and reduced drug efflux. Together, this conceptual design resulted in increased cell killing in vitro and decreased tumour growth in vivo without compromising safety.
A well-established mechanism of action for BIBF is its antiangiogenic properties 21 , which is relevant for the in vivo experiments. However, antiangiogenic activity has been reported after the administration of BIBF at a dose of 100 mg kg -1 orally for five consecutive days 21 . In our studies, we administered BIBF only once per week, which would probably not be sufficient for an antiangiogenic effect.
Numerous EC clinical trials have explored the use of smallmolecule inhibitors as single agents. To date, only a handful of treatments have improved survival, with the best results seen with antiangiogenic agents (bevacizumab 45 and cediranib 46 ). However, these treatments only extend progression-free survival by an average of three months. These data suggest that combinatorial strategies that target specific Achilles' heels in each tumour must be designed to improve the long-term survival for patients with EC. Data from this study provide the proof-of-concept that synthetic lethality using PTX can be achieved in LOF p53 tumours by the addition of BIBF to the treatment regimen. These findings may extend beyond EC to other cancer types that are typified by TP53 mutations, such as NSCLC and ovarian cancer, for which the combination of BIBF with chemotherapy has improved survival 22, 23 .
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41565-017-0009-7.
Cell culture. Ishikawa H (Ishikawa, type I EC) and Hec50co EC cells (USC), a subline of Hec50 cells, were provided by E. Gurpide (New York University) 47,48 , and KLE cells (USC) were purchased from the American Type Culture Collection. Hec50co cells that stably express p53 R175H GOF (GOF Hec50co, USC) have been described previously 15 . Ishikawa and Hec50co cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Invitrogen) supplemented with 1% Pen/Strep (100 U ml -1 , Gibco) and 10% FBS (Atlanta Biologicals). KLE cells were cultured in RPMI-1640 medium (Gibco) supplemented with 1% Pen/Strep and 10% FBS. GOF Hec50co cells were cultured as Hec50co cells with the addition of 0.8 mg ml -1 G418 to maintain stable p53 R175H expression (Gibco). All the cells were maintained in a humidified incubator (infrared direct heat CO 2 incubator (Sanyo Scientific Autoflow) at 37 °C under a 5% CO 2 flow. All the cell lines were authenticated by CODIS marker testing, and were mycoplasma-free as determined by a MycoAlert mycoplasma detection kit (Lonza).
Cell viability assay.
Two days prior to adding the treatments, Ishikawa, Hec50co and GOF Hec50co cells were plated at a density of 10 3 cells per well, whereas the slower-growing KLE cells were plated at 0.5 × 10 4 cells per well, in 96 well plates. Treatments were added in a volume of 50 µ l per well after the addition of 150 µ l of fresh medium. The untreated control group was incubated with 200 µ l per well of fresh medium. Three days later, the contents of the 96 well plates were aspirated, replaced by 100 µ l of fresh medium and 20 µ l MTS reagent (MTS, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in each well (CellTiter 96 Aqueous One Solution Reagent (Promega Corporation)), and incubated at 37 °C with 5% CO 2 for 1-4 h. The absorbance was recorded at 490 nm using a Spectra Max plus 384 Microplate Spectrophotometer (Molecular Devices). Relative cell viability values were expressed as the percentage of the absorbance from the treated wells compared with that from the control wells (untreated), given that the control wells viability was set to 100%. For experiments in which both the concomitant and sequential administration of PTX and BIBF were evaluated (Fig. 1b) , Hec50co cells were seeded at 10 3 cells per well for 48 h. The first treatment was added for another 48 h, washed away and then the second treatment was added for an extra 72 h, followed by assessment of the viability. The untreated control group was incubated with fresh medium for five days. The synergy between PTXs and BIBFs was evaluated in Hec50co cells through the establishment of dose-response curves of PTXs, BIBFs or the combination using varied concentrations of PTXs and either 1 µ M BIBFs or 100 nM BIBFs. Cytotoxicity was estimated using the MTS assay as stated above. CI values were calculated by utilizing the dose-response curve data in the CompuSyn software (ComboSyn Inc.): CI < 1 indicates synergy.
NP fabrication and characterization. NP fabrication. NPs were prepared using a nanoprecipitation method as illustrated in Fig. 2a . Briefly, 5 mg of drug (PTX (LC Laboratories) or BIBF (Selleck Chemicals)) and 100 mg PLGA 75:25 (M w , 68 kDa; inherent viscosity, 0.59 dl g -1 (Durect Corporation)) or PLGA 50:50 (M w , 24-38 kDa; inherent viscosity, 0.32-0.44 dl g -1 (Resomer RG 503 H (Boehringer Ingelheim KG)) were dissolved in 4.25 ml of acetone (Fisher Scientific) and 0.75 ml of 97% ethanol (Sigma-Aldrich). This organic phase was added to a 10 ml syringe with a needle size of G26, placed such that the tip was submerged just below the surface of a stirred 50 ml aqueous solution that contained 0.1% w/v surfactant (PVA, M w 8-9 kDa, 80% hydrolysed (Sigma-Aldrich) or TPGS (Sigma-Aldrich)) in a 150 ml beaker. The formed suspension was left on the stirrer for 45 min and then the rest of the organic solvent was evaporated under reduced pressure of 40 mbar using a Laborota 4000 rotary evaporator (Heidolph) for 4 h. The NPs were then washed with nanopure water and collected using Amicon ultra-15 centrifugal filter units (M w cutoff = 100 kDa (EMD Millipore)) at 500g for 15 min four times using an Eppendorf centrifuge 5804 R (Eppendorf). The NPs were freshly prepared before each experiment. For the data shown in Fig. 3a,b , PTXp (75/T) and PTXp (75/P) were prepared on the first day and stored overnight at 4 °C, and then PTXp (50/T) and PTXp (50/P) were prepared on the second day, when all the treatments were initiated. This staggered preparation resulted from experimental limitations associated with NP fabrication, as the preparation of each batch takes ~6-7 h.
Estimation of DL and EE. NPs were dissolved in acetonitrile and the drug content was estimated through HPLC-ultraviolet (HPLC-UV) for PTX and a HPLC-MS for BIBF. The PTX content in the NPs was quantified using HPLC-UV (2690 Alliance separation module coupled with a 2487 dual λ absorbance detector (Waters)). A reverse-phase 5 µ m C-18 column, 100 Å, 4.5 × 250 mm (Waters) was utilized in the assay and isocratic elution with a mobile phase of acetonitrile (Fisher Scientific): water (60:40, v/v) at a flow rate of 1 ml min -1 was used. The detection wavelength λ was set at 227 nm and the injection volume was 100 µ l. The BIBF content was determined using HPLC-MS (Shimadzu Model 2010A liquid chromatograph and mass spectrometer (Shimadzu)) using a LC-10AD VP Solvent Delivery system. A Synergi 4 µ m Polar-RP column, 80 Å, 2 × 150 mm (Phenomenex Inc.) was used. Isocratic elution was utilized with a mobile phase composed of water + 0.1% formic acid (Fisher Scientific):acetonitrile + 0.1% formic acid (50:50, v/v), at a flow rate of 0.2 ml min -1 . Electrospray ionization was used, a m/z ratio of 540.5 was utilized and 25 µ l was injected.
DLs and EEs were calculated from the following formulas: NP size and zeta potential determination. A NP suspension of 0.05 mg ml -1 was prepared in water. Size and zeta potential were then measured using a Zetasizer Nano ZS particle analyser (Malvern Instrument Ltd).
Microscopic evaluation of NPs. SEM. The surface morphology of the prepared NPs was examined using SEM. Briefly, a NP suspension of 0.05 mg ml -1 was added onto a silicon wafer mounted on an aluminium SEM stub. The suspensions were allowed to air dry for 24 h. They were then coated with gold and palladium by an argonbeam K550 sputter coater (Emitech Ltd). Images were captured using the Hitachi S-4800 scanning electron microscope (Hitachi High-Technologies) operated at a 3 kV accelerating voltage.
Confocal laser scanning microscopy. Qualitative cell-uptake studies of the prepared NPs were carried out using confocal microscopy. Briefly, RHD (Sigma)loaded PLGA NPs (RHDp) were prepared by the nanoprecipitation method as described previously, except that the drug was substituted by an equivalent amount of RHD. The RHD content in RHDp was calculated by dissolving the NPs in dimethyl sulfoxide and then comparing the RHD fluorescence with a constructed calibration curve (data not shown). RHD fluorescence was measured at an excitation λ of 540 nm and emission λ of 625 nm using a SpectraMax M5 multimode microplate reader (Molecular Devices). Hec50co cells were plated at a density of 10 4 cells in clear, four-chamber glass slides with a lid (Lab-Tek, Nunc), and incubated for 48 h (37 °C, 5% CO 2 ). RHDp that contained 0.01 µ g RHD were then added to each chamber, leaving untreated cells as a control, and incubated with the cells for 4 h (cells in the Z-stacked confocal image were incubated for 24 h with RHDp (75/T) (Fig. 2d) ). The medium was removed and the cells were washed twice with Hank's balanced salt solution (Gibco). Cell membranes were stained by adding 0.5 ml of a pre-warmed cell mask deep red plasma membrane staining solution (Invitrogen) at 5 µ g ml -1 in each chamber, incubated for 5 min at 37 °C, washed and replaced by 0.5 ml of fresh medium for another 5 min. The medium was then aspirated and washed twice with phosphate-buffered saline (PBS, Gibco). Then, 0.5 ml of a 4% paraformaldehyde (Electron Microscopy Sciences (EMS)) fixative solution was added and incubated for 10 min at 37 °C. The specimen was mounted with a Vectashield Hardset medium containing 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories) to stain the nuclei. Cellular fluorescence was observed using confocal laser scanning microscopy (Carl Zeiss 710 (Zeiss)) equipped with Zen 2009 imaging software. The images were processed using Image J open access software, version 1.47 (National Institutes of Health).
TEM. The size and shape of PTXp prepared from PLGA (75:25) and TPGS surfactant (PTXp (75/T)) were also measured by a JEOL JEM-1230 TEM equipped with a Gatan UltraScan 1000 2k × 2k CCD acquisition system (JEOL USA Inc.). An aliquot of 10 µ l of the NP suspension (0.05 mg ml -1 ) was added for 30 s on a carboncoated, glow-discharged 400-mesh TEM copper grid by Auto 306 (BOC Edwards) that was pre-coated with a Formvar 0.5% solution in an ethylene dichloride film (EMS). Whatman filter paper was then used to remove any excess liquid and the grid was air dried. The TEM images were processed using Image J. The cellular uptake of PTXp (75/T) was further confirmed through TEM. HEC50co cells were seeded at 10 6 cells in a 100 mm petri dish for 24 h. PTXp (75/T) at a concentration equivalent to 5 nM PTX was then incubated with the cells for another 24 h. Cells were then fixed with 2.5% glutaraldehyde (EMS) in a 0.1 M sodium cacodylate buffer (EMS), pH 7.4, for 30 min, rinsed twice with a 0.1 M cacodylate buffer, pH 7.4, for 4 min each. Osmium tetroxide (1% (EMS)) was then added for 30 min to increase the electron density and improve the fixation efficiency. Fixed cells were then washed twice with distilled water and stained with 2.5% uranyl acetate (EMS) for 5 min. Dehydration of the sample was performed gradually using 25%, 50%, 75% and 95% ethanol, each for 4 min, and finally twice with 100% ethanol for 5 min each. Dehydrated samples were infiltrated with ethanol: Epon (Ted Pella Inc.) mixture (1:1) for 30 min, and then embedded in Epon at 70 °C for 8 h. Thin sections of 60-80 nm were cut using a Leica EM UC6 Ultramicrotome MZ6 (Reichert Technologies), and, finally, these sections were mounted on a Formvar-coated 400-mesh TEM copper grid, counter stained with 5% uranyl acetate and Reynold's lead citrate (80 mM lead nitrate (Sigma) in 164 mM sodium citrate buffer (RPI)). The sample was imaged, and then processed using Image J.
Semi-quantitative uptake of NPs by flow cytometry. Semi-quantitative cell uptake was carried out using FACScan flow cytometer (Becton Dickinson) and analysed using FlowJo software (TreeStar Inc.). Ishikawa, Hec50co and GOF Hec50co cells were plated at a density of 10 5 cells, whereas KLE cells were plated at a density of 0.5 × 10 6 cells in 12 well plates. One day later, an equivalent amount of RHDp that contained 0.01 µ g RHD was added to each well in a serum-free medium, and untreated cells were used as the control. After 6 h, the cells were washed with PBS twice, trypsinized, quenched with serum-containing medium, centrifuged at 230g for 5 min, resuspended in 300 µ l of fresh medium and kept on ice until the analysis was performed. Serum-free medium was used to accelerate the uptake process of these particles and thus differences in the magnitude of NP uptake could be easily detected over a short period of incubation 49 .
PTX in vitro release. PTX release studies from different formulations were performed by adding PTXp equivalent to 1 µ g PTX in 1 ml of 1% v/v aqueous Tween 80 solution (Fisher Scientific) into 1.5 ml amber microcentrifuge tubes. The samples were incubated at 37 °C in a horizontal shaker at 300 revolutions per minute. At each time point, three tubes were centrifuged at 20,817g for 20 min at 5 °C, the supernatant was discarded and the amount of drug remaining in particles was estimated by dissolving the pellet in acetonitrile, vortexing for 10 min and finally analysing using HPLC. The total amount released at each time point was calculated by subtracting the amount of PTX that remained in the pellet from the original amount of PTX added to each tube.
Cell cycle analysis by flow cytometry. Cells were plated in 100 mm dishes with an equal number of cells in each dish and treated with either 1 µ M BIBFs, 40 nM PTXp (75/T) or a combination of both for 24 h. Cells were fixed in 70% ethanol. After washing with PBS, cells were incubated in Krishan's solution (3.8 mM sodium citrate (Fisher Scientific), 0.014 mM propidium iodide (AnaSpec), 1% NP-40 (Sigma) and 2.0 mg ml -1 RNase A (Fisher Scientific)) for 30 min at 37 °C and analysed by a FACScan flow cytometer as previously described 16 . The data were subjected to further analysis by CellQuest software version 3.3, which was used to generate DNA histograms that indicated the fractions of the cell population in the sub-G1, G0-G1, S or G2/M phase of the cell cycle. Corresponding author(s): Aliasger K Salem
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Experimental design 1. Sample size
Describe how sample size was determined. Sample sizes for in vivo experiments were estimated based on preliminary data in order to achieve 80% power to detect significant differences between groups. All animal experiments were not blinded
Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
All invitro experiments were repeated twice (n=3 biological replicates), and all attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For in vivo experiment, mice were randomized after tumor challenge, directly before initiating treatments, in order to achieve average tumor volume of 50 mm3 per group.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was carried out due to the quantitative nature of data collection and/ or analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
